TW202337496A - 治療新生血管性年齡相關性黃斑點退化之方法 - Google Patents

治療新生血管性年齡相關性黃斑點退化之方法 Download PDF

Info

Publication number
TW202337496A
TW202337496A TW112109645A TW112109645A TW202337496A TW 202337496 A TW202337496 A TW 202337496A TW 112109645 A TW112109645 A TW 112109645A TW 112109645 A TW112109645 A TW 112109645A TW 202337496 A TW202337496 A TW 202337496A
Authority
TW
Taiwan
Prior art keywords
weeks
dose
patient
vegf antagonist
vegf
Prior art date
Application number
TW112109645A
Other languages
English (en)
Chinese (zh)
Inventor
傑佛瑞 大衛 卡恩斯
祖法 穆玉克弗
烏富克 奧爾加克
艾蒂安 皮傑奧雷特
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202337496A publication Critical patent/TW202337496A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW112109645A 2022-03-17 2023-03-15 治療新生血管性年齡相關性黃斑點退化之方法 TW202337496A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263320796P 2022-03-17 2022-03-17
US63/320,796 2022-03-17
US202263386380P 2022-12-07 2022-12-07
US63/386,380 2022-12-07

Publications (1)

Publication Number Publication Date
TW202337496A true TW202337496A (zh) 2023-10-01

Family

ID=85873755

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112109645A TW202337496A (zh) 2022-03-17 2023-03-15 治療新生血管性年齡相關性黃斑點退化之方法

Country Status (5)

Country Link
US (1) US20250197486A1 (https=)
EP (1) EP4493589A1 (https=)
JP (1) JP2025509568A (https=)
TW (1) TW202337496A (https=)
WO (1) WO2023175549A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
TW202116802A (zh) * 2019-09-13 2021-05-01 瑞士商諾華公司 治療眼部疾病之方法

Also Published As

Publication number Publication date
EP4493589A1 (en) 2025-01-22
US20250197486A1 (en) 2025-06-19
WO2023175549A1 (en) 2023-09-21
JP2025509568A (ja) 2025-04-11

Similar Documents

Publication Publication Date Title
US20260098085A1 (en) Methods for treating age-related macular degeneration
AU2021286278C1 (en) Methods for treating ocular diseases
TW202337496A (zh) 治療新生血管性年齡相關性黃斑點退化之方法
JP7828274B2 (ja) 眼疾患を治療するための方法
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂
US20230416351A1 (en) Vegf antagonist for use in methods for treating ocular diseases
RU2776850C2 (ru) Способы лечения глазных заболеваний
RU2771900C2 (ru) Способ лечения болезней глаз
JP2026072102A (ja) 眼疾患を治療するための方法